Rechallenge of everolimus for metastatic renal cell carcinoma after recovery from grade 3 interstitial lung disease: a case report

We report a case of the rechallenge of everolimus for metastatic renal cell carcinoma (RCC) after successful recovery from grade 3 interstitial lung disease (ILD). A 76-year-old man with metastatic RCC developed grade 3 ILD one month after the initiation of everolimus therapy (10 mg/day). ILD subsid...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hinyokika kiyo. Acta urologica Japonica 2014-01, Vol.60 (1), p.25-28
Hauptverfasser:	Utsunomiya, Noriaki, Kono, Yuka, Matsumoto, Keiyu, Matsumoto, Takeshi, Nakagawa, Atsushi, Tsunemori, Hiroyuki, Okada, Takuya, Muguruma, Koei, Kawakita, Mutsushi
Format:	Artikel
Sprache:	jpn
Schlagworte:	Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Carcinoma, Renal Cell - secondary Carcinoma, Renal Cell - therapy Enzyme Inhibitors - administration & dosage Enzyme Inhibitors - adverse effects Everolimus Fatal Outcome Humans Kidney Neoplasms - secondary Kidney Neoplasms - therapy Lung Diseases, Interstitial - chemically induced Lung Diseases, Interstitial - drug therapy Male Prednisolone - administration & dosage Severity of Illness Index Sirolimus - administration & dosage Sirolimus - adverse effects Sirolimus - analogs & derivatives TOR Serine-Threonine Kinases - antagonists & inhibitors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We report a case of the rechallenge of everolimus for metastatic renal cell carcinoma (RCC) after successful recovery from grade 3 interstitial lung disease (ILD). A 76-year-old man with metastatic RCC developed grade 3 ILD one month after the initiation of everolimus therapy (10 mg/day). ILD subsided in 4 months after the withdrawal of everolimus and treatment with corticosteroids. Half dose (5 mg/day) of everolimus was rechallenged for 9 months until another grade 3 ILD developed. Everolimus kept the disease under control for 13 months including the discontinuation period.
ISSN:	0018-1994